Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors

LEXINGTON, Mass., March 31, 2019 /PRNewswire/ -- Cyteir Therapeutics, a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases, announced the presentation of promising new ...

from PR Newswire: https://ift.tt/2YAEeqh